Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.
AN2 Therapeutics, Inc. reports clinical-stage biopharmaceutical developments tied to novel small-molecule therapeutics derived from its boron chemistry platform. Company updates center on infectious-disease programs such as Chagas disease, NTM lung disease caused by Mycobacterium abscessus and melioidosis, along with oncology, hematologic-disease and other research programs.
Recurring ANTX news includes clinical and regulatory updates for candidates such as epetraborole and AN2-502998, investigator-initiated trial activity, operating and financial results, material agreements, governance matters and investor conference participation.
AN2 Therapeutics, Inc. (NASDAQ: ANTX) announced the appointment of Maggie FitzPatrick to its Board of Directors. FitzPatrick, a seasoned corporate affairs executive, previously held leadership roles at Johnson & Johnson and Cigna. She is recognized for her expertise in corporate affairs and marketing in healthcare. President and CEO Eric Easom welcomed her, highlighting the expected positive impact on the company's mission to address serious infectious diseases. AN2 is currently developing epetraborole, an oral treatment for NTM lung disease.
AN2 Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of its initial public offering (IPO) of 4,600,000 shares at $15.00 each, aiming to raise $69.0 million. The IPO is set to begin trading on Nasdaq under the symbol ANTX on March 25, 2022, and is expected to close on March 29, 2022. The underwriters also hold a 30-day option to purchase an additional 690,000 shares. The funds raised are intended to support AN2’s development of epetraborole, an oral treatment for rare infectious diseases.